The HIt HArd and hiT Early in Multiple Sclerosis Trial
NCT07517185
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG:
Sequential treatment with rituximab and cladribine
Sponsor
Uppsala University